Solving MedTech trial complexity with the right technology partner

MedTech companies developing connected devices, diagnostics, or Software as a Medical Device (SaMD), are under pressure to run highly complex clinical trials in systems that were never designed for them. As devices become more digital and data‑driven, trials generate massive volumes of information across pre‑market and post‑market studies.

Meanwhile, regulatory expectations continue to intensify. Teams must demonstrate rigorous documentation, enforce strict data‑privacy practices, and maintain full traceability. But in reality, study teams and sites are often juggling multiple logins, switching between incompatible platforms, and stitching together processes that were never built to work together, let alone support modern MedTech trials.

This fragmentation slows execution, increases the risk of errors, and makes it nearly impossible to maintain a clear, real‑time view of study performance from early feasibility through post‑market surveillance.

In this blog, we’ll break down why MedTech trials have become so complex, how modular eClinical systems and expanding data demands sit at the center of this challenge, and what teams should look for in a technology partner capable of bringing everything together in one unified environment.

The goal of MedTech trials MedTech trials are structured clinical studies designed to evaluate whether a medical device or software solution is safe, effective, and performs as intended in real-world conditions. Unlike traditional pharma trials, device, diagnostics, and SaMD studies often involve:

• Device performance metrics - such as reliability, accuracy, usability, and functional behavior across different scenarios
• Physiological measurements - objective clinical signals collected from participants to assess safety and overall impact on the body
• Patient‑reported outcomes - insights directly from users about comfort, symptoms, ease of use, or quality‑of‑life changes
• Real‑world evidence - data captured during everyday use that reveals how the technology performs beyond controlled environments

The goal of a MedTech trial is to generate credible, high‑quality clinical evidence that demonstrates safety, performance, and meaningful patient benefit, evidence that becomes the foundation for regulatory approval, market adoption, and real‑world clinical use.1

Why MedTech trials are more complex than ever

MedTech trials operate in a uniquely and increasingly demanding environment where multiple factors intersect:

1. Fragmented eClinical Systems

As we explore in our recent blog, “Why compliance risk increases in modular eClinical setups,” most trial teams rely on modular eClinical setups, where documentation, data capture, monitoring, and communication are handled in separate tools. 2

This threatens timelines and data quality due to:

• Duplicate work across systems
• Manual data reconciliation
• Increased risk of inconsistencies

2. Evolving Global Regulations

Regulatory requirements vary across regions such as the EU, US, and China. Teams must continuously adapt to:

• Changing compliance frameworks (MDR, IVDR, FDA)
• Cross-border data transfer restrictions
• Increasingly rigorous audit requirements

3. Data Explosion from Devices

Modern MedTech solutions generate continuous streams of data. Without proper integration, this creates:

• Multiple data formats
• Validation challenges
• Delays in analysis and reporting

Together, these challenges make MedTech trials feel significantly heavier and more complicated than other types of studies in the life‑science space.

The core problem: data fragmentation

Most MedTech trial challenges, from slow execution to compliance risk, stem from one core issue: data fragmentation. Data fragmentation in clinical trials occurs when data, documentation, and communication are stored across disconnected systems, making it difficult to access, validate, and act on information in real time.

Because every system stores data differently, even simple tasks, like verifying performance metrics or matching source data to case report forms, become slow and error‑prone. This disconnect also amplifies the challenges of meeting global privacy rules, since fragmented tools often handle sensitive data inconsistently across regions with different requirements.

As MedTech solutions generate more real‑world data, from device readings to patient‑reported outcomes, fragmentation multiplies the volume of files, formats, and workflows teams must manage. Instead of getting a clear, connected view of their data, teams end up repeating tasks, dealing with mismatched information, and fixing issues by hand just to keep the study on track.

What to look for in a MedTech technology partner

Choosing the right technology partner is essential for running efficient and reliable MedTech trials. Because these studies come with unique challenges, ranging from smaller patient groups to more frequent device updates, it’s important to work with a partner who understands these differences and can support them effectively. A strong partner should offer more than a software; they should help simplify complexity, improve communication, and reduce the operational load that often slows MedTech teams down.

When evaluating a partner, look for someone who:

• Understands MedTech‑specific needs, not just pharma workflows
• Supports flexible study designs as devices evolve and change during trials
• Reduces fragmentation by centralizing documentation, data capture, and communication
• Ensures global data‑privacy compliance across regions with different rules
• Improves communication between all stakeholders

A unified platform like oomnia brings all of this together by centralizing documentation, communication, and trial data in one unified Clinical Research Information System (CRIS). By keeping everything in one place, oomnia helps reduce manual work, improves collaboration between sponsors and sites, and provides the clarity MedTech teams need to run more efficient and predictable trials.

Why unified clinical trial software is the future of MedTech trials

The most effective way to eliminate fragmentation is to move to a unified system. Unified clinical trial software provides a single source of truth for all study activities.

Within one shared environment, teams no longer have to resolve conflicting datasets or search for information across different platforms. Study decisions become faster, data becomes easier to trust, and operational workflows stay much more streamlined.

This aligns with the findings of Lottes et al., who note that successful medical innovation depends on strong communication between clinicians, researchers, industry, and regulators, noting that this collaboration is essential for moving new technologies into real clinical use.3 Since communication is so critical, having all trial information in one system naturally supports this, making interactions clearer, reducing misunderstandings, and helping every stakeholder stay aligned throughout the study.

How oomnia unifies MedTech trials

oomnia is a natively-unified clinical trial platform built as a Clinical Research Information System (CRIS), designed specifically to reduce the fragmentation that slows down medical device and SaMD studies.

With configurable templates, automated workflows, and streamlined site collaboration, teams can launch studies faster while reducing administrative effort. Compliance is built- in from the start, with oomnia supporting MDR, IVDR, and FDA submission needs and providing ISO 13485‑aligned documentation, complete traceability, and full audit trails.

Unlike traditional pharma‑oriented platforms, it offers only the features MedTech teams require, keeping costs predictable and workflows clean. By centralizing global coordination, device‑specific data capture, long‑term evidence generation, and regulatory‑ready workflows, oomnia helps MedTech teams run more efficient, connected, and inspection‑ready trials, all in a single system.

Real‑world impact for MedTech teams

This approach is reflected in oomnia’s work with Centinel Spine, where adaptability and close collaboration were essential to supporting complex MedTech clinical operations.

Working directly with James Kuras, Vice President of Clinical Affairs and Operations at Centinel Spine, the oomnia team engaged deeply throughout the development of the EDC, site and patient interfaces, and metric capabilities. Rather than using predefined workflows, the focus was on understanding the study early and aligning objectives, operations, and execution from the start.

As James Kuras explains,

“Their system is not a one‑size‑fits‑all solution, and they adapt to the needs of the sponsor, sites, physicians, and the study requirements.”

This approach resulted in a system purpose‑built for the realities of MedTech trials, one that unifies health and clinical data across stakeholders and turns information into something not only compliant and visible, but genuinely actionable.

Interested in seeing how oomnia supports real‑world MedTech trials?

Explore how a unified approach can streamline execution and support your path to market. Request a demo!

References

Kalinowska-Beszczyńska, O., & Prędkiewicz, K. (2024). MedTech start-ups: A comprehensive scoping review of current research trends and future directions. PloS one, 19(8), e0307959. https://doi.org/10.1371/journal.pone.0307959

Wemedoo. (2026). Why compliance risk increases in modular eClinical setups. Accessed April 3, 2026. https://wemedoo.com/blogs/why-compliance-risk-increases-in-modular-eClinical-setups/

Lottes, A. E., Cavanaugh, K. J., Chan, Y. Y., Devlin, V. J., Goergen, C. J., Jean, R., Linnes, J. C., Malone, M., Peat, R., Reuter, D. G., Taylor, K., & Wodicka, G. R. (2022). Navigating the Regulatory Pathway for Medical Devices-a Conversation with the FDA, Clinicians, Researchers, and Industry Experts. Journal of cardiovascular translational research, 15(5), 927–943. https://doi.org/10.1007/s12265-022-10232-1